FDA registered labeler

Johnson & Johnson Innovative Medicine

Transforming healthcare through transformative therapies

New Brunswick, NJMarket cap $380B+24 listed NDC records shown
At a glance

Johnson & Johnson Innovative Medicine is the FDA labeler of record for Darzalex, Stelara, Tremfya and others. 2 of its brands bill under a HCPCS code: Darzalex (J9145), Stelara (J3357).

Brand portfolio

Each brand opens the FDA registry filtered to that product.

J-code portfolio

Clinician-administered products from this labeler that carry a HCPCS code.

HCPCS codes for Johnson & Johnson Innovative Medicine brands
BrandCodeDescriptorBillable unit
DarzalexJ9145Injection, daratumumab, 10 mg10 mg = 1 Unit
StelaraJ3357Injection, ustekinumab, IV, 1 mg1 mg = 1 Unit

Registered NDC product lines

Other manufacturers